Weekly Analysts’ Ratings Updates for Omeros (OMER)

Omeros (NASDAQ: OMER) recently received a number of ratings updates from brokerages and research firms:

• 4/1/2025 – Omeros had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
• 4/1/2025 – Omeros had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.
• 3/21/2025 – Omeros was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 3/21/2025 – Omeros had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.
• 3/13/2025 – Omeros was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 3/5/2025 – Omeros was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 2/20/2025 – Omeros had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.

Omeros Stock Down 3.8 %

Shares of NASDAQ OMER traded down $0.31 during midday trading on Tuesday, reaching $7.91. The company had a trading volume of 1,877,015 shares, compared to its average volume of 542,466. The stock has a market cap of $458.38 million, a PE ratio of -3.42 and a beta of 2.03. Omeros Co. has a one year low of $2.61 and a one year high of $13.60. The firm’s fifty day moving average price is $8.66 and its 200-day moving average price is $7.58.

Institutional Trading of Omeros

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Omeros by 3.6% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,831 shares of the biopharmaceutical company’s stock valued at $314,000 after acquiring an additional 1,110 shares during the period. Truvestments Capital LLC grew its position in shares of Omeros by 116.5% in the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 1,669 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in shares of Omeros by 79.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company’s stock valued at $44,000 after buying an additional 1,972 shares during the period. Ameriprise Financial Inc. raised its holdings in shares of Omeros by 2.0% during the fourth quarter. Ameriprise Financial Inc. now owns 120,493 shares of the biopharmaceutical company’s stock valued at $1,190,000 after acquiring an additional 2,317 shares in the last quarter. Finally, Cerity Partners LLC lifted its stake in Omeros by 9.9% in the fourth quarter. Cerity Partners LLC now owns 28,989 shares of the biopharmaceutical company’s stock worth $286,000 after acquiring an additional 2,600 shares during the period. Institutional investors own 48.79% of the company’s stock.

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.